XNCR Trading Analysis - 10/20/2026 04:17 PM — TRU-SENTIMENT

XNCR (Xencor Inc.) at $24.73. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $1,880 vs put $0. RSI 38.5.

TRU-SENTIMENT · DeltaNeutral

XNCR Trading Analysis - 10/20/2026 04:17 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

XNCR (Xencor Inc.) at $24.73. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $1,880 vs put $0. RSI 38.5.

Symbol
XNCR
Price
$24.73
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-20 16:17:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

From TRUE SENTIMENT OPTIONS data (2026-10-20):

Call Volume: $1,880.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $1,880.00

  • Sentiment: Bullish (call_pct 100.0, put_pct 0.0).
  • Directional conviction: 4 call contracts, 0 put, 1 call trade — pure bullish bet via delta 40-60 filter.
  • Near-term expectation: Options flow implies upside anticipation despite weak technicals.
  • Divergence: Technicals bearish (RSI 38.52, MACD neg) vs sentiment bullish — spread recommendation flags "divergence detected".
Note: Options flow shows 100% call dollar volume at delta 40-60 conviction, but total analyzed true sentiment options only 1 (filter ratio 1.2%).

Key Statistics: XNCR

$24.73 +7.48%
52-Week Range
$10.38 - $30.61
Market Cap
$1.84B
P/E (TTM)
59.50
PEG Ratio
N/A
Beta
1.17
Next Earnings
N/A
Avg Volume
$933,523
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)59.50
EPS (trailing 12 mo)$-2.16
Market cap$1.84B
Shares outstanding74.4M

Dividend

Dividend yield0.00%

Risk & range

Beta1.17
52-week low$10.38
52-week high$30.61
Historical volatility45.9%

Ownership & trading

Institutional ownership59.7%
Average daily volume1.4M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context:

Xencor (XNCR) is a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies for cancer and autoimmune diseases. Based on general knowledge, recent context likely includes:

  • Pipeline updates from ongoing Phase 1/2 trials in immuno-oncology, with potential interim data readouts expected in late 2026.
  • Positive preclinical data presented at major medical conferences (e.g., ASH or ASCO) supporting XmAb platform advancements.
  • Potential partnership or licensing news with larger pharma players seeking bispecific antibody expertise.
  • No confirmed earnings date in provided data, but historical fiscal year end is 2025-12-01, suggesting next annual reporting in early 2026.
  • Context: Headlines of pipeline progress may contrast with weak technicals (RSI 38.52, price below SMAs), while options sentiment shows bullish conviction — possible anticipation of catalysts not yet reflected in price.

Fundamental Analysis:

Based strictly on embedded FUNDAMENTALS data for XNCR:

  • Trailing P/E: 59.50; Trailing EPS: -2.16 (negative earnings, typical for clinical-stage biotech).
  • Market Cap: $1,838,749,690; Shares Outstanding: 74,353,000; Institutional Ownership: 59.71%.
  • Dividend Yield: 0.00%; No dividend declared (ex-dividend date null).
  • Beta: 1.17 (moderate volatility vs market); 52-Week High: $30.61; 52-Week Low: $10.38.
  • Average Volume: 1,369,000; Historical Volatility: 45.86%.
  • Revenue growth, gross/operating/net margins, ROE, Debt/Equity, Free Cash Flow, PEG, forward PE/EPS, price-to-book, total revenue, analyst target price: all null in data — not available for comparison.
  • Valuation: High trailing P/E of 59.50 with negative EPS indicates market prices in future pipeline success, not current profitability. No PEG to assess growth-adjusted value.
  • Fundamentals diverge from technicals: negative EPS and high beta coincide with weak price trend (below SMAs) but options sentiment is bullish.

Current Market Position:

From minute bars (2026-10-19 to 2026-10-20) and daily history:

  • Daily close on 2026-10-19: $23.01; Intraday last bar 2026-10-20 15:50: close $24.73 (up from 09:45 open $22.99 two-day span).
  • Recent daily action: 2026-10-16 close $22.93, 2026-10-19 low $21.97 (30-day low), rebound to $23.01.
  • Minute bars show recovery: 2026-10-19 09:45 low $22.27, by 2026-10-20 15:35 high $25.00, close $24.73.
  • Intraday momentum: Rising from $22.37 (10-19 09:45) to $24.73 (10-20 15:50), volume spike 10-19 at 1,308,714.
Support
$21.97
Resistance
$25.02
Recent Close
$24.73
30d High
$26.49
Bollinger Lower
$22.85

Technical Analysis:

Technical Indicators

Current Price
$23.01
SMA 5
$23.42
SMA 20
$24.36
SMA 50
$25.07
RSI 14
38.52
MACD
-0.30
Signal
-0.24
Histogram
-0.06
Bollinger Mid
$24.36
Bollinger Upper
$25.86
Bollinger Lower
$22.85
ATR 14
$1.35
30d High
$26.49
30d Low
$21.97
  • SMA alignment: Price $23.01 < SMA5 $23.42 < SMA20 $24.36 < SMA50 $25.07 — bearish stack, no golden cross.
  • RSI 38.52: Weak momentum, approaching oversold (<30) but not yet.
  • MACD -0.30 below signal -0.24, histogram -0.06: Bearish momentum persisting.
  • Bollinger: Price $23.01 between lower $22.85 and mid $24.36 — near lower band, no squeeze (width $3.01).
  • 30-day range: Price at $23.01 is 13% above low $21.97, 13% below high $26.49.

True Sentiment Analysis (Delta 40-60 Options):

From TRUE SENTIMENT OPTIONS data (2026-10-20):

Call Volume: $1,880.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $1,880.00

  • Sentiment: Bullish (call_pct 100.0, put_pct 0.0).
  • Directional conviction: 4 call contracts, 0 put, 1 call trade — pure bullish bet via delta 40-60 filter.
  • Near-term expectation: Options flow implies upside anticipation despite weak technicals.
  • Divergence: Technicals bearish (RSI 38.52, MACD neg) vs sentiment bullish — spread recommendation flags "divergence detected".
Note: Options flow shows 100% call dollar volume at delta 40-60 conviction, but total analyzed true sentiment options only 1 (filter ratio 1.2%).

Key Price Levels (observational only):

Support (30d Low)
$21.97
Bollinger Lower
$22.85
SMA 5
$23.42
SMA 20 / BB Mid
$24.36
SMA 50
$25.07
30d High
$26.49

Interactive charts load with JavaScript. This text is the crawlable summary.